Cargando…

High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin

BACKGROUND: Several systemic inflammatory response (SIR) markers, including platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and albumin-to-globulin ratio (AGR), have emerged as prognostic markers in various cancers. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Huh, Gunn, Ryu, Ji Kon, Chun, Jung Won, Kim, Joo Seong, Park, Namyoung, Cho, In Rae, Paik, Woo Hyun, Lee, Sang Hyub, Kim, Yong-Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510111/
https://www.ncbi.nlm.nih.gov/pubmed/32967632
http://dx.doi.org/10.1186/s12885-020-07390-3
_version_ 1783585722336280576
author Huh, Gunn
Ryu, Ji Kon
Chun, Jung Won
Kim, Joo Seong
Park, Namyoung
Cho, In Rae
Paik, Woo Hyun
Lee, Sang Hyub
Kim, Yong-Tae
author_facet Huh, Gunn
Ryu, Ji Kon
Chun, Jung Won
Kim, Joo Seong
Park, Namyoung
Cho, In Rae
Paik, Woo Hyun
Lee, Sang Hyub
Kim, Yong-Tae
author_sort Huh, Gunn
collection PubMed
description BACKGROUND: Several systemic inflammatory response (SIR) markers, including platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and albumin-to-globulin ratio (AGR), have emerged as prognostic markers in various cancers. The aim of this study was to explore the impact of SIR markers on the survival outcomes of unresectable intrahepatic cholangiocarcinoma (IHC) patients. METHODS: Patients with histologically confirmed, unresectable IHC treated with gemcitabine plus cisplatin (GP) chemotherapy in a single tertiary hospital from 2012 to 2016 were retrospectively reviewed. Progression-free survival (PFS) and overall survival (OS) were determined using unadjusted Kaplan-Meier and adjusted Cox-proportional-hazards analysis. Time-dependent receiver operating characteristic (ROC) analysis was performed to compare the performance of the SIR markers in predicting OS. RESULTS: A total of 137 patients received a median of six cycles (interquartile range [IQR], 3–11) of GP chemotherapy with a median observation time of 9.9 months (range, 1.8–54.7 months). The median PFS and OS of all patients were 7.8 months and 9.9 months, respectively. Among the SIR markers, high PLR (> 148) and high NLR (> 5) were associated with a short PFS (Hazard ratio [HR] 1.828, P = 0.006; HR 1.738, P = 0.030, respectively) and short OS (HR 2.332, P < 0.001; HR 2.273, P < 0.001, respectively). Low LMR (< 3.5) and low AGR (< 1.2) were associated with a short OS (HR 2.423, P < 0.001; HR 1.768, P = 0.002, respectively). In multivariable cox-regression analysis, high PLR (HR 1.766, P = 0.009) and distant lymph node (LN) metastasis (HR 2.085, P = 0.001) were associated with a short PFS. High PLR (HR 1.856, P = 0.002) was an independent predictor of a short OS, along with distant LN metastasis (HR 1.929; P < 0.001), low LMR (HR 1.691; P = 0.041), and low level of serum albumin (< 3.5 g/dL) (HR 1.632; P = 0.043). Time-dependent ROC analysis revealed that the area under the curve of PLR for predicting overall survival was greater than that of NLR, LMR, and AGR at most time points. CONCLUSIONS: High PLR was an independent prognostic factor of a short PFS and OS in patients with unresectable IHC receiving GP chemotherapy.
format Online
Article
Text
id pubmed-7510111
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75101112020-09-24 High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin Huh, Gunn Ryu, Ji Kon Chun, Jung Won Kim, Joo Seong Park, Namyoung Cho, In Rae Paik, Woo Hyun Lee, Sang Hyub Kim, Yong-Tae BMC Cancer Research Article BACKGROUND: Several systemic inflammatory response (SIR) markers, including platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and albumin-to-globulin ratio (AGR), have emerged as prognostic markers in various cancers. The aim of this study was to explore the impact of SIR markers on the survival outcomes of unresectable intrahepatic cholangiocarcinoma (IHC) patients. METHODS: Patients with histologically confirmed, unresectable IHC treated with gemcitabine plus cisplatin (GP) chemotherapy in a single tertiary hospital from 2012 to 2016 were retrospectively reviewed. Progression-free survival (PFS) and overall survival (OS) were determined using unadjusted Kaplan-Meier and adjusted Cox-proportional-hazards analysis. Time-dependent receiver operating characteristic (ROC) analysis was performed to compare the performance of the SIR markers in predicting OS. RESULTS: A total of 137 patients received a median of six cycles (interquartile range [IQR], 3–11) of GP chemotherapy with a median observation time of 9.9 months (range, 1.8–54.7 months). The median PFS and OS of all patients were 7.8 months and 9.9 months, respectively. Among the SIR markers, high PLR (> 148) and high NLR (> 5) were associated with a short PFS (Hazard ratio [HR] 1.828, P = 0.006; HR 1.738, P = 0.030, respectively) and short OS (HR 2.332, P < 0.001; HR 2.273, P < 0.001, respectively). Low LMR (< 3.5) and low AGR (< 1.2) were associated with a short OS (HR 2.423, P < 0.001; HR 1.768, P = 0.002, respectively). In multivariable cox-regression analysis, high PLR (HR 1.766, P = 0.009) and distant lymph node (LN) metastasis (HR 2.085, P = 0.001) were associated with a short PFS. High PLR (HR 1.856, P = 0.002) was an independent predictor of a short OS, along with distant LN metastasis (HR 1.929; P < 0.001), low LMR (HR 1.691; P = 0.041), and low level of serum albumin (< 3.5 g/dL) (HR 1.632; P = 0.043). Time-dependent ROC analysis revealed that the area under the curve of PLR for predicting overall survival was greater than that of NLR, LMR, and AGR at most time points. CONCLUSIONS: High PLR was an independent prognostic factor of a short PFS and OS in patients with unresectable IHC receiving GP chemotherapy. BioMed Central 2020-09-23 /pmc/articles/PMC7510111/ /pubmed/32967632 http://dx.doi.org/10.1186/s12885-020-07390-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Huh, Gunn
Ryu, Ji Kon
Chun, Jung Won
Kim, Joo Seong
Park, Namyoung
Cho, In Rae
Paik, Woo Hyun
Lee, Sang Hyub
Kim, Yong-Tae
High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
title High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
title_full High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
title_fullStr High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
title_full_unstemmed High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
title_short High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
title_sort high platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510111/
https://www.ncbi.nlm.nih.gov/pubmed/32967632
http://dx.doi.org/10.1186/s12885-020-07390-3
work_keys_str_mv AT huhgunn highplatelettolymphocyteratioisassociatedwithpoorprognosisinpatientswithunresectableintrahepaticcholangiocarcinomareceivinggemcitabinepluscisplatin
AT ryujikon highplatelettolymphocyteratioisassociatedwithpoorprognosisinpatientswithunresectableintrahepaticcholangiocarcinomareceivinggemcitabinepluscisplatin
AT chunjungwon highplatelettolymphocyteratioisassociatedwithpoorprognosisinpatientswithunresectableintrahepaticcholangiocarcinomareceivinggemcitabinepluscisplatin
AT kimjooseong highplatelettolymphocyteratioisassociatedwithpoorprognosisinpatientswithunresectableintrahepaticcholangiocarcinomareceivinggemcitabinepluscisplatin
AT parknamyoung highplatelettolymphocyteratioisassociatedwithpoorprognosisinpatientswithunresectableintrahepaticcholangiocarcinomareceivinggemcitabinepluscisplatin
AT choinrae highplatelettolymphocyteratioisassociatedwithpoorprognosisinpatientswithunresectableintrahepaticcholangiocarcinomareceivinggemcitabinepluscisplatin
AT paikwoohyun highplatelettolymphocyteratioisassociatedwithpoorprognosisinpatientswithunresectableintrahepaticcholangiocarcinomareceivinggemcitabinepluscisplatin
AT leesanghyub highplatelettolymphocyteratioisassociatedwithpoorprognosisinpatientswithunresectableintrahepaticcholangiocarcinomareceivinggemcitabinepluscisplatin
AT kimyongtae highplatelettolymphocyteratioisassociatedwithpoorprognosisinpatientswithunresectableintrahepaticcholangiocarcinomareceivinggemcitabinepluscisplatin